MedPath

Measuring survival of transfused red blood cells in patients with Sickle cell disease and ß-Thalassemia: A Biotin Label approach

Recruiting
Conditions
Sickle cell disease & ß-thalassemia
Registration Number
NL-OMON25329
Lead Sponsor
Amsterdam UMC - location AMC
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
15
Inclusion Criteria

•Patient with either sickle cell disease (HbSS/HbSß0/HbSC/HbSß+) or ß-thalassemia (major or transfusion dependent thalassemia intermedia)
•Currently on chronic transfusion program.
•>18 years of age

Exclusion Criteria

No venous access for blood drawings

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome is the survival of transfused RBCs in patients with sickle cell disease and ß-thalassemia.
Secondary Outcome Measures
NameTimeMethod
Inter patient study parameters will focus on the effects of the transfusion. The main parameters will be:<br>•Inflammatory/immunomodulatory response on transfused RBCs.<br>•Influence of previous responder status on RBC survival.<br>•Antibody formation to the biotin label.<br><br>Intra patient study parameters will focus on the effect of matching of the RBC units. Both units will be matched differentially. <br>The main parameters will be:<br>•The recovery, short term and long term survival of both RBC units.<br>•The (immediate and late) host immune response to both RBC units by measuring effect on expression of markers of clearance and inflammation as well as transcriptome analysis.<br>
© Copyright 2025. All Rights Reserved by MedPath